Background The Ad26.COV2.S vaccine is a recombinant, replication-incompetent human
adenovirus type 26 vector encoding full-length severe acute respiratory syndrome coronavirus …

A safe and effective vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
may be required to end the coronavirus disease 2019 (COVID-19) pandemic 1 , 2 , 3 , 4 …

Background Efficacious vaccines are urgently needed to contain the ongoing coronavirus
disease 2019 (Covid-19) pandemic of infection with severe acute respiratory syndrome …

Previously we demonstrated a correlation between a nonsyncytium-inducing (NSI), non-T-cell
line tropic phenotype of HIV-1 isolates and the capacity to replicate in primary monocyte-…

The third variable (V3) domain has been implicated in determining the human immunodeficiency
virus (HIV) phenotype, including fusion capacity and monocytotropism. In a large set of …

The Ad26.COV2.S vaccine 1 , 2 – 3 has demonstrated clinical efficacy against symptomatic
COVID-19, including against the B.1.351 variant that is partially resistant to neutralizing …

Background The Ad26.COV2.S vaccine was highly effective against severe–critical coronavirus
disease 2019 (Covid-19), hospitalization, and death in the primary phase 3 efficacy …

Importance Control of the global COVID-19 pandemic will require the development and
deployment of safe and effective vaccines. Objective To evaluate the immunogenicity of the Ad26…

Durability of Response after Ad26.COV2.S Vaccination In this study, investigators measured
immune responses in 20 participants who had received either one or two doses of the Ad26.…

Broadly neutralizing HIV antibodies (bNAbs) can recognize carbohydrate-dependent epitopes
on gp120. In contrast to previously characterized glycan-dependent bNAbs that recognize …